Analytical Data
-
基因名
TPBG/5T4
- Application
-
别名
5T4 oncofetal trophoblast glycoprotein Short name: 5T4 oncotrophoblast glycoprotein Wnt-activated inhibitory factor 1 Short name: WAIF1
-
种属
Rat
-
表达系统
E. coli
-
标签
N- His-SUMO
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q5PQV5
-
表达区间
32-361aa
-
分子量
51.8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TPBG (Trophectoderm Protein Beta Gene) and its variant 5T4 are tumor-associated antigens that have garnered significant attention in cancer research. Initially identified as a marker for the trophoblast tissue during early embryonic development, TPBG/5T4 expression has been found to be upregulated in various malignancies, including colorectal, lung, and breast cancers. This aberrant expression pattern makes TPBG/5T4 a promising target for immunotherapy and cancer diagnostics. Researchers have been investigating its role in tumorigenesis, particularly how it contributes to the immune evasion of cancer cells. Additionally, studies are focused on developing monoclonal antibodies and vaccines aimed at enhancing the immune response against tumors expressing TPBG/5T4. The potential for TPBG/5T4 to serve as both a biomarker for early detection and a target for targeted therapy underlines its significance in the development of personalized cancer treatment strategies. Ongoing research aims to elucidate the mechanisms governing TPBG/5T4 expression in tumors, explore its interaction with various immune pathways, and assess its efficacy in clinical settings. Collectively, this line of research holds the promise of improving therapeutic outcomes for patients with cancers that exhibit TPBG/5T4 expression.
